title: [Pergolide use and heart valve fibrosis. Yearly control in patients with Parkinson disease who use pergolide].
authors.affiliation: Afd. Neurologie, Universitair Medisch Centrum Groningen, Groningen. t.van.laar@neuro.umcg.nl
authors.forename: Teus
authors.initials: T
authors.lastname: van Laar
authors.forename: Henk
authors.initials: H
authors.lastname: Berendse
authors.forename: Bas R
authors.initials: BR
authors.lastname: Bloem
authors.forename: Agnita J W
authors.initials: AJ
authors.lastname: Boon
authors.forename: Johannes J
authors.initials: JJ
authors.lastname: van Hilten
authors.forename: Ad
authors.initials: A
authors.lastname: Hovestadt
authors.forename: Marina A J
authors.initials: MA
authors.lastname: de Koning-Tijssen
authors.forename: Peter C G
authors.initials: PC
authors.lastname: Nijssen
authors.forename: Wim E J
authors.initials: WE
authors.lastname: Weber
mesh_terms: D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004452:Echocardiography; D005355:Fibrosis / Q000139:chemically induced* / Q000453:epidemiology; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy; D010479:Pergolide / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D018491:Dopamine Agonists; D010479:Pergolide